Nothing Special   »   [go: up one dir, main page]

BRPI0513020A - moduladores de andrÈgenio, seus usos, composição farmacêutica, formulação farmacêutica tópica e artigo de fabricação - Google Patents

moduladores de andrÈgenio, seus usos, composição farmacêutica, formulação farmacêutica tópica e artigo de fabricação

Info

Publication number
BRPI0513020A
BRPI0513020A BRPI0513020-4A BRPI0513020A BRPI0513020A BR PI0513020 A BRPI0513020 A BR PI0513020A BR PI0513020 A BRPI0513020 A BR PI0513020A BR PI0513020 A BRPI0513020 A BR PI0513020A
Authority
BR
Brazil
Prior art keywords
article
pharmaceutical composition
manufacture
pharmaceutical formulation
modulators
Prior art date
Application number
BRPI0513020-4A
Other languages
English (en)
Inventor
Mark Laurence Boys
Victoria Leigh Downs
Daniel Yunlong Du
William Glen Harter
Lain-Yen Hu
Bruce Allen Lefker
Huangshu Lei
Donna Michele Iula
Yvonne Dorothy Smith
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35079243&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0513020(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of BRPI0513020A publication Critical patent/BRPI0513020A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/54—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/18—Systems containing only non-condensed rings with a ring being at least seven-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/42—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing seven carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cosmetics (AREA)

Abstract

MODULADORES DE ANDROGêNIO, SEUS USOS, COMPOSIçãO FARMACêUTICA, FORMULAçãO FARMACêUTICA TóPICA E ARTIGO DE FABRICAçãO. A presente invenção refere-se a um nova classe de 4-cicloalcóxi benzonitrilas e a seu uso como moduladores de receptor de androgênio. Outros aspectos da invenção refere-se ao uso destes compostos para diminuir secções de sebo em excesso e para estimular crescimento de cabelo.
BRPI0513020-4A 2004-07-08 2005-06-27 moduladores de andrÈgenio, seus usos, composição farmacêutica, formulação farmacêutica tópica e artigo de fabricação BRPI0513020A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US58616004P 2004-07-08 2004-07-08
US59803304P 2004-08-02 2004-08-02
PCT/IB2005/001999 WO2006006065A1 (en) 2004-07-08 2005-06-27 Androgen modulators

Publications (1)

Publication Number Publication Date
BRPI0513020A true BRPI0513020A (pt) 2008-04-22

Family

ID=35079243

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0513020-4A BRPI0513020A (pt) 2004-07-08 2005-06-27 moduladores de andrÈgenio, seus usos, composição farmacêutica, formulação farmacêutica tópica e artigo de fabricação

Country Status (15)

Country Link
US (2) US7670613B2 (pt)
EP (1) EP1781598A1 (pt)
JP (1) JP4874965B2 (pt)
AR (1) AR049965A1 (pt)
BR (1) BRPI0513020A (pt)
CA (1) CA2570047C (pt)
GT (1) GT200500187A (pt)
MX (1) MXPA06015169A (pt)
NL (1) NL1029457C2 (pt)
PA (1) PA8639001A1 (pt)
PE (1) PE20060379A1 (pt)
SV (1) SV2006002169A (pt)
TW (1) TW200605876A (pt)
UY (1) UY29008A1 (pt)
WO (1) WO2006006065A1 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2006003700A0 (en) 2004-02-13 2006-08-31 Warner Lambert Co Androgen receptor modulators
JP2007532621A (ja) 2004-04-13 2007-11-15 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー アンドロゲンモジュレータ
EP1740533A1 (en) * 2004-04-22 2007-01-10 Warner-Lambert Company LLC Androgen modulators
EP1781598A1 (en) 2004-07-08 2007-05-09 Warner-Lambert Company LLC Androgen modulators
EP1781599A1 (en) * 2004-08-18 2007-05-09 Warner-Lambert Company LLC Androgen modulators
TW200724139A (en) * 2005-05-05 2007-07-01 Warner Lambert Co Androgen modulators
US8359450B2 (en) * 2009-02-13 2013-01-22 Opnet Technologies, Inc. Memory utilization analysis
KR102668696B1 (ko) 2012-01-12 2024-05-29 예일 유니버시티 E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
US10071164B2 (en) 2014-08-11 2018-09-11 Yale University Estrogen-related receptor alpha based protac compounds and associated methods of use
AU2016209349B2 (en) * 2015-01-20 2020-05-07 Arvinas, Inc. Compounds and methods for the targeted degradation of the Androgen Receptor
US20170327469A1 (en) 2015-01-20 2017-11-16 Arvinas, Inc. Compounds and methods for the targeted degradation of androgen receptor
WO2017079267A1 (en) 2015-11-02 2017-05-11 Yale University Proteolysis targeting chimera compounds and methods of preparing and using same
KR20190038840A (ko) 2016-07-15 2019-04-09 앵스띠뛰 파스퇴르 피부 및/또는 모발 복구를 위한 5-하이드록시트립타민 1b 수용체-자극제
CN110506039A (zh) 2016-10-11 2019-11-26 阿尔维纳斯股份有限公司 用于雄激素受体靶向降解的化合物和方法
CN115175901B (zh) 2019-12-19 2024-03-22 阿尔维纳斯运营股份有限公司 用于雄激素受体的靶向降解的化合物和方法
AU2021273458A1 (en) 2020-05-09 2022-12-01 Arvinas Operations, Inc. Methods of manufacturing a bifunctional compound, ultrapure forms of the bifunctional compound, and dosage forms comprising the same

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6124343A (en) * 1919-01-27 2000-09-26 Rhone-Poulenc Rorer Limited Substituted phenyl compounds with a substituent having a thienyl ring
US3535365A (en) * 1967-11-29 1970-10-20 Merck & Co Inc Preparation of 2,6-dichloro-4-methoxy-benzonitrile
SU469247A3 (ru) 1972-01-14 1975-04-30 Майлз Лабораториз Инк (Фирма) Способ получени производных хромона
US4029493A (en) * 1973-02-23 1977-06-14 Mobil Oil Corporation Substituted phenoxybenzonitriles as herbicides
FR2397387A1 (fr) * 1976-04-27 1979-02-09 Serobiologiques Lab Sa 4,4'-bis-formyl-polyhalo-diphenoxyalcanes, procede de preparation et application a la synthese de 4,4'-dicyano-polyhalo-diphenoxyalcanes
US4234595A (en) * 1977-07-13 1980-11-18 Mead Johnson & Company 3-Indolyl-tertiary butylaminopropanols
DE2862100D1 (en) 1977-10-12 1983-01-05 Ici Plc Acylanilides, process for their manufacture and pharmaceutical and veterinary compositions containing them
US4567201A (en) 1981-11-25 1986-01-28 Takeda Chemical Industries, Ltd. Diphenoxypropane derivatives and compositions of antiasthmatic and antiinflammatory agents thereof
GB8504093D0 (en) 1985-02-18 1985-03-20 Ici Plc Alkene alkyne/cycloalkylene derivatives
LU88769I2 (fr) 1982-07-23 1996-11-05 Zeneca Ltd Bicalutamide et ses sels et esters pharmaceutiquement acceptables (Casodex (R))
DE3382646D1 (de) * 1982-08-26 1993-01-28 Merck Patent Gmbh Cyclohexanderivate und ihre verwendung als komponenten fluessigkristalliner-dielektrika.
JPS59144747A (ja) 1983-02-04 1984-08-18 Chisso Corp ２−クロロ−４−アルキルオキシベンゾニトリル化合物
US4536321A (en) * 1983-02-18 1985-08-20 Chisso Corporation Fluorobenzene derivatives and liquid crystal compositions containing the same
JPS63227502A (ja) 1987-03-17 1988-09-21 Sds Biotech Kk 防菌防カビ剤
US4992433A (en) * 1987-11-23 1991-02-12 Janssen Pharmaceutica N.V. Novel pyridazinamine derivatives
US4925590A (en) * 1988-03-10 1990-05-15 Merck Patent Gesellschaft Mit Beschrankter Haftung Derivatives of 4-cyano-2,3-difluorophenol
DE3825170A1 (de) 1988-07-23 1990-01-25 Hoechst Ag, 65929 Frankfurt Substituierte 5-(4-(4,5-dihydro-2-oxazolyl)-phenoxyalkylenoxyalkyl)-isoxazole, verfahren sowie 5-(phenoxyalkylenoxyalkyl)-isoxazole als zwischenprodukte zu ihrer herstellung und ihre verwendung zur bekaempfung von krankheiten, die durch infektion mit viren hervorgerufen wurden
DE4017019A1 (de) 1990-05-26 1991-11-28 Hoechst Ag Verwendung von substituierten ss-hydroxyethylaminen als potente hemmstoffe der exoenzyme von pilzen
JPH04124183A (ja) 1990-09-14 1992-04-24 Mitsubishi Rayon Co Ltd 光学活性パントラクトン誘導体
JP3088777B2 (ja) 1991-03-27 2000-09-18 富士薬品工業株式会社 新規光学分割剤及びそれを用いる光学活性アミンの製造方法
JP3151929B2 (ja) 1992-05-15 2001-04-03 大日本インキ化学工業株式会社 フルオロシクロヘキセン誘導体
DE4217928A1 (de) 1992-05-30 1993-12-02 Hoechst Ag Neue Mischungen aus Herbiziden und Antidots, neue (Hetero-)Aryloxy-Verbindungen, Verfahren zu deren Herstellung, diese enthaltenden Mittel und deren Verwendung
JPH0641038A (ja) 1992-07-17 1994-02-15 Mitsubishi Kasei Corp カルボン酸誘導体
US5455274A (en) 1992-12-09 1995-10-03 Ciba-Geigy Corporation Hydroxyamidine derivatives
US5316755A (en) * 1993-02-02 1994-05-31 Sterling Winthrop Inc. Compositions of iodophenoxy alkanes and iodophenyl ethers for visualization of the gastrointestinal tract
GB2278054A (en) 1993-05-18 1994-11-23 Zeneca Ltd Compounds for the treatment of urinary incontinence
TW262553B (pt) 1994-03-17 1995-11-11 Hitachi Seisakusyo Kk
CN1147206A (zh) 1994-04-21 1997-04-09 耐克麦德英梅金公司 含有药用粘土的x-射线造影组合物
JPH07309850A (ja) 1994-05-16 1995-11-28 Canon Inc 光学活性化合物、それを含有する液晶組成物、それを有する液晶素子及びそれらを用いた表示方法、表示装置
AU682947B2 (en) 1994-05-27 1997-10-23 Mochida Pharmaceutical Co., Ltd. Novel azolyl methyl phenyl derivatives having aromatase inhibitory activity
ATE210657T1 (de) 1994-10-14 2001-12-15 Merck Patent Gmbh Zns wirksames (r)-(-)-2-(5-(4-fluorophenyl)-3- pyridylmethylaminomethyl)chroman
JP3802581B2 (ja) * 1995-03-01 2006-07-26 富山化学工業株式会社 新規なビフェニル誘導体またはその塩およびそれらを含有する抗炎症剤
JPH0953018A (ja) * 1995-06-09 1997-02-25 Mitsubishi Chem Corp フタロシアニン誘導体及び該誘導体を使用した光学記録媒体
US5656651A (en) * 1995-06-16 1997-08-12 Biophysica Inc. Androgenic directed compositions
DE19534209A1 (de) * 1995-09-15 1997-03-20 Jenapharm Gmbh Hormonales Mittel zur Behandlung der Haut
ES2127106B1 (es) * 1996-03-21 1999-11-16 Menarini Lab Derivados benzopiranicos con accion antagonista de los leucotrienos, procedimiento para su preparacion y utilizacion de los mismos.
US5847166A (en) * 1996-10-10 1998-12-08 Massachusetts Institute Of Technology Synthesis of aryl ethers
US6071957A (en) * 1996-11-27 2000-06-06 The University Of Tennessee Research Corporation Irreversible non-steroidal antagonist compound and its use in the treatment of prostate cancer
EP1019384A1 (en) 1997-02-04 2000-07-19 Dong Wha Pharmaceutical Industrial Co. Ltd. 3-amino-1,2-benzoisoxazole derivatives, process for preparation, and use thereof
US6013668A (en) 1997-08-13 2000-01-11 Bristol-Myers Squibb Company Enantiomers of 4-[[(cyanoimino) [(1,2,2-trimethylpropyl) amino]methyl]amino]benzonitrile
US6297239B1 (en) 1997-10-08 2001-10-02 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US6184249B1 (en) 1998-12-18 2001-02-06 Biophysica, Inc. Androgen receptor suppressors in the therapy and diagnosis of prostate cancer, alopecia and other hyper-androgenic syndromes
CZ2002711A3 (cs) * 1999-08-27 2003-11-12 Ligand Pharmaceuticals Incorporated Modulátory androgenních receptorů, způsoby jejich výroby a způsoby jejich použití
US20020065303A1 (en) 2000-02-01 2002-05-30 Bing-Yan Zhu Bivalent phenylene inhibitors of factor Xa
WO2002006196A1 (en) 2000-07-13 2002-01-24 Merck Patent Gmbh Chiral compounds i
EA007101B1 (ru) * 2000-08-24 2006-06-30 Юниверсити Оф Теннесси Рисерч Фаундейшн Селективные модуляторы андрогенового рецептора и способы их применения
CZ2003467A3 (cs) 2000-08-31 2004-04-14 Pfizer Inc. Fenoxybenzylaminové deriváty jako selektivní inhibitory reuptake serotoninu
DE60138468D1 (de) * 2000-09-06 2009-06-04 Emisphere Tech Inc Cyanophenoxy-carbonsäuren und zusammensetzungen für die freisetzung aktiver substanzen
DE60135862D1 (de) * 2000-10-06 2008-10-30 Mitsubishi Tanabe Pharma Corp Aliphatische stickstoffhaltige fünfgliedrige ringverbindungen
AU2002236775A1 (en) 2001-01-16 2002-07-30 Seok-Ki Choi Sodium channel modulators
WO2002060896A1 (en) 2001-01-31 2002-08-08 Pfizer Products Inc. Ether derivatives useful as inhibitors of pde4 isozymes
ES2385659T3 (es) 2001-04-10 2012-07-27 Pfizer, Inc. Derivados de pirazol para tratar VIH
AR035700A1 (es) 2001-05-08 2004-06-23 Astrazeneca Ab Derivados de arilheteroalquilamina, composicion farmaceutica, usos de estos derivados para la fabricacion de medicamentos, metodos de tratamiento, y proceso para la preparacion de estos derivados
DK1480634T3 (da) 2002-02-07 2011-11-14 Univ Tennessee Res Foundation Selektive androgenreceptormodulatorer (SARM) til behandling af benign prostatahyperplasi
TW200302722A (en) 2002-02-13 2003-08-16 Astrazeneca Ab Therapeutic agents
CN1633287A (zh) * 2002-02-15 2005-06-29 恩多研究公司 联苯衍生物及其作为抗雄激素试剂的应用
CN1646479A (zh) 2002-02-28 2005-07-27 田纳西大学研究基金会 不可逆选择性雄激素受体调节剂及其使用方法
WO2003082787A1 (en) 2002-03-26 2003-10-09 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
US6875438B2 (en) * 2002-04-27 2005-04-05 Aventis Pharma Deutschland Gmbh Preparations for topical administration of substances having antiandrogenic activity
DE10218963A1 (de) * 2002-04-27 2003-11-20 Aventis Pharma Gmbh Zubereitungen zur topischen Applikation von antiandrogen wirksamen Substanzen
US6951884B2 (en) * 2002-06-12 2005-10-04 Hoffmann-La Roche Inc. Fluorobenzamides and uses thereof
WO2004018477A2 (en) 2002-08-14 2004-03-04 Ciba Specialty Chemicals Holdings Inc. Liquid crystal display and colour filter with improved transparency for green light
EP1556038A2 (en) 2002-08-26 2005-07-27 Merck & Co., Inc. Acetophenone potentiators of metabotropic glutamate receptors
PL374732A1 (en) * 2002-09-19 2005-10-31 Abbott Laboratories Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-iv (dpp-iv)
WO2004110994A1 (en) 2003-06-18 2004-12-23 Pfizer Products Inc. Novel piperazinyl-aryloxy and piperazinyl-heteroaryloxy-n-aryl lactams
FI20030958A0 (fi) 2003-06-27 2003-06-27 Orion Corp Uusia yhdisteitä
WO2005013914A2 (en) 2003-08-08 2005-02-17 Vertex Pharmaceuticals Incorporated Heteroarylaminosulfonylphenyl derivatives for use as sodium or calcium channel blockers in the treatment of pain
GB0324551D0 (en) 2003-10-21 2003-11-26 Karobio Ab Novel compounds
EP1687274A1 (en) 2003-11-20 2006-08-09 Warner-Lambert Company LLC Androgen receptor modulators
AP2006003700A0 (en) 2004-02-13 2006-08-31 Warner Lambert Co Androgen receptor modulators
JP2007532621A (ja) 2004-04-13 2007-11-15 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー アンドロゲンモジュレータ
EP1740533A1 (en) 2004-04-22 2007-01-10 Warner-Lambert Company LLC Androgen modulators
KR101193464B1 (ko) 2004-05-07 2012-10-24 얀센 파마슈티카 엔.브이. １１-베타 하이드록시스테로이드 탈수소효소 저해제로서의아다만틸 피롤리딘-２-온 유도체
EP1781598A1 (en) 2004-07-08 2007-05-09 Warner-Lambert Company LLC Androgen modulators
EP1781599A1 (en) 2004-08-18 2007-05-09 Warner-Lambert Company LLC Androgen modulators
ATE392419T1 (de) 2004-08-31 2008-05-15 Warner Lambert Co Androgenmodulatoren
ES2318577T3 (es) 2004-10-29 2009-05-01 Eli Lilly And Company Derivados de cicloalquil lactama como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa 1'.
TW200724139A (en) 2005-05-05 2007-07-01 Warner Lambert Co Androgen modulators

Also Published As

Publication number Publication date
PA8639001A1 (es) 2006-06-02
WO2006006065A1 (en) 2006-01-19
US20100048517A1 (en) 2010-02-25
EP1781598A1 (en) 2007-05-09
JP4874965B2 (ja) 2012-02-15
NL1029457C2 (nl) 2006-08-02
CA2570047A1 (en) 2006-01-19
NL1029457A1 (nl) 2006-01-10
AR049965A1 (es) 2006-09-20
GT200500187A (es) 2006-02-17
CA2570047C (en) 2010-09-28
SV2006002169A (es) 2006-02-15
UY29008A1 (es) 2006-03-31
US7670613B2 (en) 2010-03-02
MXPA06015169A (es) 2007-08-21
PE20060379A1 (es) 2006-05-27
TW200605876A (en) 2006-02-16
US20060009427A1 (en) 2006-01-12
JP2008505880A (ja) 2008-02-28

Similar Documents

Publication Publication Date Title
BRPI0513020A (pt) moduladores de andrÈgenio, seus usos, composição farmacêutica, formulação farmacêutica tópica e artigo de fabricação
UY31080A1 (es) Derivados de pirazol sustituidos con heteroarilo utiles para tratar trastornos hiperproliferativos y enfermedades asociadas con angiogénesis
UY31294A1 (es) Derivados de tetrahidrocarbozol, métodos para obtenerlos, formulaciones que los contienen y usos de los mismos
SV2011003948A (es) Uso de una composicion espumable esencialmente libre de ingredientes con actividad farmaceutica para el tratamiento de la piel humana
ECSP088102A (es) Compuestos para el tratamiento de infecciones bacterianas resistentes a múltiples fármacos
UY31079A1 (es) Derivados de fenilaminobenceno sustituidos de utilidad para el tratamiento de trastornos y enfermedades hiperproliferativos asociados con actividad quinasa extracelular mediada por mitógenos
PA8632701A1 (es) Compuestos terapeuticos
UY33346A (es) Compuestos y metodos para la modulacion de quinasa e indicaciones de la misma
EA200970853A1 (ru) Композиции для личной гигиены с улучшенной доставкой ароматизатора
BR112013011634A2 (pt) derivados de 2,3-di-hidroimidazol[1,2-c]quinazolina substituídos por aminoálcool úteis para tratar os distúrbios hiperproliferativos e as doenças associadas com a angiogênese derivados de 2,3-di-hidroimidazol[1,2-c]
BRPI0508540A (pt) composto, composição farmacêutica, e, uso de um composto
BR112013004766A2 (pt) 2-amino-quinolina-3-carboxamidas substituídas como moduladores de kcnq2/3
CO5640037A2 (es) Derivados de la quinazolina para el tratamiento del cancer
ECSP055572A (es) Derivados ciclotiocarbamativos como moduladores pr y el uso de los mismos en el tratamiento de enfermedades de la piel.
UY31780A (es) Fenoxibenzamidas sustituidas
UY28702A1 (es) Derivados de quinazolina
AU2009287650A8 (en) Hair growth promoting agent containing 15,15 -difluoroprostaglandin F2alpha derivative as active ingredient
BRPI0519280A2 (pt) composto, composiÇço farmacÊutica e uso de um composto
UY28366A1 (es) Compuestos químicos
BRPI0414780A (pt) composto, uso do mesmo, composição farmacêutica, e, métodos para a terapia da dor em um animal de sangue quente, e para preparar um composto
CL2009001267A1 (es) Compuestos derivados de triciclos nitrogenados, con actividad antibacteriana; procedimiento de preparacion; composicion farmceutica que los comprende; para el tratamiento de la tuberculosis.
UY28357A1 (es) Derivados de benzimidazol, composiciones que los contienen, preparación de los mismos y sus usos
UY29517A1 (es) Nueva clase de 4-lactama benzonitrilos, composiciones farmacéuticas que los contienen y aplicaciones
BRPI0406614A (pt) Composto, uso do mesmo, composição farmacêutica, métodos para a terapia de dor em um animal de sangue quente e para a terapia de distúrbios gastrointestinais funcionais em um animal de sangue quente, e, processo para preparar um composto
BRPI0514014A (pt) composto, uso do mesmo, composição farmacêutica, métodos para a terapia de dor, de ansiedade, e de mal de parkinson em um animal de sangue quente, e, processo para a preparação de um composto

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2261 DE 06/05/2014.